Innovative Therapeutics in Oncology and Neuroscience
20
Oncology
Validated and Differentiated Clinical Pipeline
Program
Preclinical
Phase I
Phase II
Phase III / Pivotal
Registration
US
Once-daily oral
Zejula (PARPi)
niraparib
XOPTUNE
GIO
Tumor Treating Fields
QINLOCK (KIT, PDGFRA)
(ripretinib)
tivdak (TF ADC)
tisotumab vedotin-tftv
for injection 40 mg
KRAZATI (KRAS G12C)
AUGTYRO (ROS1, TRK)
(repotrectinib)
Bemarituzumab (FGFR2b)
Zipalertinib (EGFR Ex20ins)
ZL-1218 (CCR8)
ZL-1310 (DLL3)
Ovarian Cancer (1st line maintenance)1
Ovarian Cancer (Platinum sensitive relapsed maintenance)1
Glioblastoma (GBM)²
Non-Small Cell Lung Cancer (NSCLC)
Brain Metastases from NSCLC
Pancreatic Cancer
Gastric Cancer³
Gastrointestinal Stromal Tumors (GIST) (4th line)4
Cervical Cancer (2nd line+ r/m) 5
Cervical Cancer (1st line r/m, combo)6*
Other tumors (mono/combo)7*
NSCLC (mono/combo)8
Colorectal Cancer (mono/combo)
ROS1+ NSCLC, NTRK+ solid tumors
FGFR2b+ Gastric/GEJ Cancer⁹
EGFR Ex20ins NSCLC10*
Solid Tumors
SCLC
US
Approved
Mainland
China
Commercial
Territories
Mainland China,
Hong Kong
and Macau
Greater China
*:
Greater China
Greater China
Greater China
US
Mainland China
Greater China
Greater China
Greater China
Global
Global
zaiLabView entire presentation